We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+30.75%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$904M
AUM Growth
+$55.5M
Cap. Flow
-$102M
Cap. Flow %
-11.32%
Top 10 Hldgs %
84.52%
Holding
24
New
4
Increased
4
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$64.5M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$60.5M
3
PCRX icon
Pacira BioSciences
PCRX
+$55.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$23.5M
5
PACB icon
Pacific Biosciences
PACB
+$13.2M

Top Sells

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$69.6M
2
ATRC icon
AtriCure
ATRC
+$69.1M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$51M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$47.5M
5
MYGN icon
Myriad Genetics
MYGN
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPPI
1
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$123M 13.55%
8,709,131
+6,688,548
+331% +$60.5M
TVTX icon
2
Travere Therapeutics
TVTX
$5.33B
$87.3M 9.65%
3,505,604
+1,067,064
+44% +$23.5M
AMRN
3
Amarin Corp
AMRN
$298M
$86.3M 9.54%
1,232,464
-8,750
-0.7% -$620K
PTCT icon
4
PTC Therapeutics
PTCT
$6.26B
$79M 8.73%
3,946,009
– –
CORT icon
5
Corcept Therapeutics
CORT
$12.7B
$74.9M 8.29%
3,882,223
-1,922,117
-33% -$28.7M
MYGN icon
6
Myriad Genetics
MYGN
$507M
$71.4M 7.9%
1,973,177
-1,294,310
-40% -$36.9M
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
$69.6M 7.7%
2,002,519
-10,000
-0.5% -$322K
GWPH
8
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$61.1M 6.76%
+602,047
New +$64.5M
AAAP
9
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$60.2M 6.66%
890,935
-978,572
-52% -$47.5M
PCRX icon
10
Pacira BioSciences
PCRX
$1.06B
$51.8M 5.73%
+1,380,134
New +$55.5M
KERX
11
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$37.1M 4.11%
5,229,455
-1,775,586
-25% -$12.8M
PACB icon
12
Pacific Biosciences
PACB
$460M
$36.2M 4.01%
6,901,428
+3,068,715
+80% +$13.2M
VCEL icon
13
Vericel Corp
VCEL
$2.43B
$18.1M 2.01%
3,024,334
+458,250
+18% +$1.76M
CVRS
14
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$18M 1.99%
11,863,353
-3,251,519
-22% -$5.45M
GMED icon
15
Globus Medical
GMED
$10.9B
$16.5M 1.82%
554,699
-2,280,301
-80% -$69.6M
ANIP icon
16
ANI Pharmaceuticals
ANIP
$1.83B
$7.51M 0.83%
143,003
– –
ADMA icon
17
ADMA Biologics
ADMA
$2.01B
$3.92M 0.43%
1,273,933
– –
STML
18
DELISTED
Stemline Therapeutics, Inc.
STML
$1.13M 0.12%
+101,420
New +$954K
CPRX
19
DELISTED
Catalyst Pharmaceutical
CPRX
$931K 0.1%
+369,298
New +$1.01M
SPNE
20
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$489K 0.05%
43,627
-10,000
-19% -$116K
ATRC icon
21
AtriCure
ATRC
$2.04B
– –
-2,849,185
Closed -$69.1M
BIOL
22
DELISTED
Biolase, Inc.
BIOL
– –
-92
Closed -$1.12M
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-544,843
Closed -$51M
SBBP
24
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-10,000
Closed -$72K

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Consonance Capital Management held 24 positions worth $904M, up 6.5% from $849M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Consonance Capital Management withdrew a net $102M in Q3 2017, closing 4 positions and reducing 9 holdings. Its most notable exit was AtriCure, an estimated $69.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $61.1M.

  • Consonance Capital Management's largest Q3 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 602,047 shares worth $61.1M.
  • Consonance Capital Management added most to Spectrum Pharmaceuticals Inc in Q3 2017, an estimated $60.5M increase.
  • Consonance Capital Management's biggest Q3 2017 reduction was Globus Medical, cutting an estimated $69.6M.
  • Consonance Capital Management fully exited AtriCure in Q3 2017, selling an estimated $69.1M.
  • Consonance Capital Management's ten largest holdings make up 85% of its $904M portfolio in Q3 2017.
  • Consonance Capital Management opened 4 new positions and closed 4 in Q3 2017.
  • Consonance Capital Management's portfolio value rose 6.5% quarter-over-quarter to $904M.

Based on Consonance Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.